Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -317.86% is 120% below its 4-year average of -144.70%, near the low end of its 4-year range (-317.86%–-72.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 74.17% below its 12-month average of -182.50%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -317.86%.
RETURN ON INVESTED CAPITAL (ROIC)
-317.86%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-182.50%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-155.05%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-74.17%
CURRENT VS 3Y AVG
-105.00%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.27%
median of 791 covered companies
CURRENT VS SECTOR MEDIAN
-801.22%
vs the sector median at left
Nuvectis Pharma, Inc.
Market Cap
$536.14M
Return on Invested Capital (ROIC)
-317.86%
TTM Avg
-182.50%
3Y Avg
-155.05%
5Y Avg
N/A
Market Cap
$535.61M
Return on Invested Capital (ROIC)
-56.99%
TTM Avg
-66.45%
3Y Avg
-57.50%
5Y Avg
-60.06%
Market Cap
$535.07M
Return on Invested Capital (ROIC)
-0.81%
TTM Avg
-8.59%
3Y Avg
-110.96%
5Y Avg
-102.03%
Market Cap
$531.78M
Return on Invested Capital (ROIC)
-43.41%
TTM Avg
-39.91%
3Y Avg
-39.91%
5Y Avg
-39.91%
Market Cap
$533.65M
Return on Invested Capital (ROIC)
-26.20%
TTM Avg
-79.72%
3Y Avg
-69.70%
5Y Avg
-51.08%
Market Cap
$531.28M
Return on Invested Capital (ROIC)
-78.31%
TTM Avg
-49.75%
3Y Avg
-41.99%
5Y Avg
-101.04%
Market Cap
$532.00M
Return on Invested Capital (ROIC)
-23.45%
TTM Avg
-110.35%
3Y Avg
-97.44%
5Y Avg
-86.64%
Market Cap
$523.67M
Return on Invested Capital (ROIC)
-16.89%
TTM Avg
-20.74%
3Y Avg
-75.97%
5Y Avg
-65.59%
Market Cap
$518.71M
Return on Invested Capital (ROIC)
-18.20%
TTM Avg
-95.31%
3Y Avg
-87.63%
5Y Avg
-71.60%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $536.14M | -317.86% | -182.50% | -155.05% | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | -56.99% | -66.45% | -57.50% | -60.06% |
| Delcath Systems, Inc. (DCTH)vs › | $535.07M | -0.81% | -8.59% | -110.96% | -102.03% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $531.78M | -43.41% | -39.91% | -39.91% | -39.91% |
| Shattuck Labs, Inc. (STTK)vs › | $533.65M | -26.20% | -79.72% | -69.70% | -51.08% |
| ProKidney Corp. (PROK)vs › | $531.28M | -78.31% | -49.75% | -41.99% | -101.04% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $532.00M | -23.45% | -110.35% | -97.44% | -86.64% |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.67M | -16.89% | -20.74% | -75.97% | -65.59% |
| Immix Biopharma, Inc. (IMMX)vs › | $518.71M | -18.20% | -95.31% | -87.63% | -71.60% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $556.23M | -25.42% | 25.46% | -12.61% | -20.42% |
ROIC
-317.9%
ROE
-306.6%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -317.86% |
| 2026-03-31 | -198.78% |
| 2025-12-31 | -149.75% |
| 2025-09-30 | -109.98% |
| 2025-06-30 | -136.15% |
| 2025-03-31 | -100.31% |
| 2024-12-31 | -204.33% |
| 2024-09-30 | -184.37% |
| 2024-06-30 | -176.11% |
| 2024-03-31 | -165.40% |
| 2023-12-31 | -187.66% |
| 2023-09-30 | -136.70% |
| 2023-06-30 | -111.10% |
| 2023-03-31 | -166.12% |
| 2022-12-31 | -135.27% |
| 2022-09-30 | -72.25% |
| 2022-06-30 | -116.97% |
| 2022-03-31 | -108.63% |
| 2021-12-31 | -304.25% |
